James Bradner, MD

Affiliations: 
Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, United States 
Google:
"James Bradner"
Mean distance: 39813
 
BETA: Related publications

Publications

You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

Remillard D, Buckley DL, Seo HS, et al. (2019) Dual Inhibition of TAF1 and BET Bromodomains from the BI-2536 Kinase Inhibitor Scaffold. Acs Medicinal Chemistry Letters. 10: 1443-1449
Bandopadhayay P, Piccioni F, O'Rourke R, et al. (2019) Neuronal differentiation and cell-cycle programs mediate response to BET-bromodomain inhibition in MYC-driven medulloblastoma. Nature Communications. 10: 2400
Sdelci S, Rendeiro AF, Rathert P, et al. (2019) MTHFD1 interaction with BRD4 links folate metabolism to transcriptional regulation. Nature Genetics
Sharifnia T, Wawer MJ, Chen T, et al. (2019) Small-molecule targeting of brachyury transcription factor addiction in chordoma. Nature Medicine
Hemming ML, Lawlor MA, Andersen JL, et al. (2019) Enhancer Domains in Gastrointestinal Stromal Tumor Regulate KIT Expression and are Targetable by BET Bromodomain Inhibition. Cancer Research
Fulciniti M, Lin CY, Samur MK, et al. (2018) Non-overlapping Control of Transcriptome by Promoter- and Super-Enhancer-Associated Dependencies in Multiple Myeloma. Cell Reports. 25: 3693-3705.e6
Brien GL, Remillard D, Shi J, et al. (2018) Targeted degradation of BRD9 reverses oncogenic gene expression in synovial sarcoma. Elife. 7
Liu S, Yosief HO, Dai L, et al. (2018) Structure-guided Design and Development of Potent and Selective Dual Bromodomain 4 (BRD4)/Polo-like Kinase 1 (PLK1) Inhibitors. Journal of Medicinal Chemistry
Wang J, Erazo T, Ferguson FM, et al. (2018) Structural and atropisomeric factors governing the selectivity of pyrimido-benzodiazipinones as inhibitors of kinases and bromodomains. Acs Chemical Biology
Xu L, Chen Y, Mayakonda A, et al. (2018) Targetable BET proteins- and E2F1-dependent transcriptional program maintains the malignancy of glioblastoma. Proceedings of the National Academy of Sciences of the United States of America
See more...